

WE CLAIM:

1. A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a polypeptide comprising SEQ ID NO:9.
2. A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9.
3. A method of treatment according to claim 1 in which the disease is characterised by IgE or Th2 differentiation.
4. A method of treatment according to claim 1 in which the disease is selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS.
5. A method of treatment according to claim 1 in which the disease is a respiratory disorder.
6. A method of treatment according to claim 1 in which the disease is asthma.
7. A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide which is capable of binding human IL13 and/or human IL4 in the presence of IL4R α or which is bound to human IL13 and/or human IL4 which comprises the amino acid sequence shown in SEQ ID NO:9.
8. A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide which comprises the amino acid sequence shown in SEQ ID NO:9 wherein the Thr

residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.

9. A method of treatment according to claim 7 or 8 in which the disease is characterised by IgE or Th2 differentiation.
10. A method of treatment according to claim 7 or 8 in which the disease is selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS.
11. A method of treatment according to claim 7 or 8 in which the disease is a respiratory disorder.
12. A method of treatment according to claim 7 or 8 in which the disease is asthma.
13. A composition comprising a soluble polypeptide comprising SEQ ID NO:9 in admixture with a carrier.
14. A composition comprising a soluble polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively, in admixture with a carrier.
15. A method of treatment of a disease characterised by IgE or Th2 differentiation, which method comprises administration to a patient of a composition according to claim 13 or 14.
16. A method of treatment of a disease selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS; which method comprises administration to a patient of a composition according to claim 13

or 14.

17. A method of treatment of a disease which is a respiratory disorder, which method comprises administration to a patient of a composition according to claim 13 or 14.

18. A method of treatment of a disease which is asthma, which method comprises administration to a patient of a composition according to claim 13 or 14.

19. A method of decreasing IL13 and/or IL4 levels in a patient's body, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9.

20. A method of decreasing IL13 and/or IL4 levels in a patient's body, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.

21. The use of a polypeptide comprising SEQ ID NO:9 or a polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively, in raising or selecting antibodies.

22. An antibody, an antibody fragment, or a synthetic construct thereof which is capable of binding to a polypeptide comprising SEQ ID NO:9 or a polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.